COMMUNIQUÉS West-GlobeNewswire

New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies
05/09/2024
Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefit VCAR33 ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with significant potential [...]
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/09/2024
WESTLAKE VILLAGE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology [...]
Cytokinetics Announces Two Presentations at the 2024 American College of Clinical Pharmacology Annual Meeting
05/09/2024
Full Data from Phase 1 Study of CK-4021586 to be Presented on September 8, 2024 SOUTH SAN FRANCISCO, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced two presentations [...]
Aurora Spine Corporation to Attend Latin America Pain Society (LAPS) Conference, Showcasing Innovations in Pain Management and Spine Care for Emerging Markets
05/09/2024
CARLSBAD, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal [...]
National Toxicology Program Report Confirms Fluoride Exposure Harms Children's IQ
05/09/2024
LAKELAND, Fla., Sept. 05, 2024 (GLOBE NEWSWIRE) -- The National Toxicology Program’s (NTP) recent report on fluoride neurotoxicity , provides compelling scientific evidence that fluoride exposure is consistently [...]
Simulated Environment Concepts, Inc. Executes a Letter of Intent (LOI) Concerning a Prospective Merger With CMR Construction & Roofing, LLC, Recognized as One of the Leading Roofing Firms in North America
05/09/2024
NASHVILLE, TN, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Simulated Environment Concepts, Inc. (OTC: SMEV or Simulated) and CMR Construction & Roofing LLC (referred to as "CMR") are pleased to announce the execution of a [...]
Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association
05/09/2024
Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association Halle (Saale) / Munich, Germany, September 5, 2024 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; [...]
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
05/09/2024
COPENHAGEN, Denmark, September 5, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial [...]
Immuron Plans Phase 2 Trial for IMM-529 following FDA review
05/09/2024
Key Points Immuron completes pre-IND meeting with FDA on the development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI) Previous clinical trial data on IMM-529 provides [...]
New data on aprocitentan to be presented at the AHA Hypertension Scientific Sessions 2024
05/09/2024
Two abstracts win the prestigious AHA 2024 Paul Dudley White International Scholar Award Allschwil, Switzerland – September 5, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, Idorsia’s [...]
BioNTX Unveils 2024 Rising Stars at the iC³® Life Science & Healthcare Innovation Summit
05/09/2024
IRVING, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- As Texas continues to grow as a biotech and healthcare innovative hub, BioNTX is honored to announce the 2024 Rising Stars, a select group of pioneering companies that [...]
Boehringer Ingelheim announces plans to advance potential new treatment for Geographic Atrophy, following positive Phase I results
05/09/2024
Ingelheim, Germany and Basel, Switzerland, September 5, 2024 – Boehringer Ingelheim and CDR-Life today announce positive results from the Phase I evaluation of BI 771716 ( Study Record | ClinicalTrials.gov ), an [...]
Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
05/09/2024
PRINCETON, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nimodipine that [...]
Acentra Health Awarded a $298 Million Contract Renewal from the Centers for Medicare & Medicaid Services to Continue Improving Care Quality for Medicare Beneficiaries
05/09/2024
The company has established the largest geographic footprint of any CMS-contracted partner for beneficiary and family centered care-quality improvement services, serving Medicare enrollees across 29 states MCLEAN, Va., [...]
Pheton Holdings Ltd Announces Pricing of Initial Public Offering
05/09/2024
BEIJING, China, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (the “Company” or “Pheton”), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products [...]
Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference
05/09/2024
CHICAGO and FORT WORTH, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for [...]
New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery
05/09/2024
YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the peer-review [...]
Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering
05/09/2024
CARLSBAD, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the pricing of a public offering of 14,724,058 shares of common stock, par value $0.001 per [...]
Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment
05/09/2024
Meeting showcases the potential role of Nexalin's neurostimulation technology in revolutionizing opioid treatment through virtual care solutions HOUSTON, TX, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. ( [...]

Pages